26
Jun
2009
Zymeworks, Inc.: Series C $3.5M
Posted in I - Series C, Q - 2Q09, R - INTERNATIONAL, X - Antibody, X - Bioinformatics, X - Therapeutic Platform
Zymeworks (Canada) a development-stage computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics, closed a $3.5M Series C financing. Participants include CTI Life Sciences Fund.
OnBioVC PARTNERS
-
